ZNTL
Zentalis Pharmaceuticals Inc.
$1.50
+$0.01(+1.01%)
55
Overall
60
Value
50
Tech
--
Quality
Market Cap
$109.65M
Volume
428.00K
52W Range
$1.01 - $4.44
Target Price
$5.74
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | -- | -- | $900.0K | $67.4M | ||
| Total Revenue | -- | -- | -- | $900.0K | $67.4M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | -- | -- | $900.0K | $67.4M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $118.8M | $216.5M | $227.3M | $299.5M | $258.6M | ||
| Research & Development | $84.9M | $175.6M | $172.7M | $189.6M | $167.8M | ||
| Research Expense | $84.9M | $175.6M | $172.7M | $189.6M | $167.8M | ||
| Selling, General & Administrative | $33.9M | $40.9M | $54.6M | $64.4M | $87.1M | ||
| General & Administrative Expenses | $33.9M | $40.9M | $54.6M | $64.4M | $87.1M | ||
| Salaries & Wages | -- | -- | $46.8M | $54.8M | $67.3M | ||
| Depreciation & Amortization | $200.0K | $500.0K | $1.4M | $1.4M | $1.3M | ||
| Depreciation & Amortization | $200.0K | $500.0K | $1.4M | $1.4M | $1.3M | ||
| Amortization | $3.7M | -- | -- | -- | -- | ||
| Other Operating Expenses | $-661.0K | $-969.0K | $-1.1M | $-857.0K | $-1.2M | ||
| OPERATING INCOME | |||||||
| Operating income | $-118.8M | $-216.5M | $-227.3M | $-299.5M | $-191.2M | ||
| EBITDA | $-118.6M | $-216.0M | $-236.2M | $-252.6M | $-164.4M | ||
| NON-OPERATING ITEMS | |||||||
| Gain on Sale of Securities | -- | -- | -- | -- | $7.9M | ||
| Other Income/Expense | -- | $-49.8M | $6.0M | $16.0M | $-5.2M | ||
| SPECIAL ITEMS | |||||||
| Special Income Charges | -- | $-8.8M | -- | -- | $-3.7M | ||
| Impairment of Capital Assets | -- | $8.8M | -- | -- | $3.7M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-118.8M | $-216.5M | $-237.6M | $-253.9M | $-165.7M | ||
| Pre-Tax Income | $-118.1M | $-164.6M | $-221.3M | $-276.9M | $-165.7M | ||
| INCOME TAX | |||||||
| Tax Provision | $444.0K | $-297.0K | $-469.0K | $-601.0K | $177.0K | ||
| NET INCOME | |||||||
| Net Income | $-117.8M | $-158.7M | $-236.8M | $-292.2M | $-165.8M | ||
| Net Income (Continuing Operations) | $-117.8M | $-158.7M | $-237.1M | $-292.3M | $-165.9M | ||
| Net Income (Discontinued Operations) | $-117.8M | $-158.7M | $-236.8M | $-292.2M | $-165.8M | ||
| Net Income (Common Stockholders) | $-117.8M | $-158.7M | $-236.8M | $-292.2M | $-165.8M | ||
| Normalized Income | -- | -- | -- | -- | $-160.3M | ||
| TOTALS | |||||||
| Total Expenses | $118.8M | $216.5M | $227.3M | $299.5M | $258.6M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $28.1M | $42.7M | $52.9M | $65.4M | $71.1M | ||
| Average Shares Outstanding (Diluted) | -- | $42.7M | $52.9M | $65.4M | $71.1M | ||
| Shares Outstanding | $41.0M | $45.6M | $59.4M | $71.0M | $71.8M | ||
| Basic EPS | -- | $-3.72 | $-4.48 | $-4.47 | $-2.33 | ||
| Basic EPS (Continuing Operations) | -- | $-3.72 | $-4.48 | $-4.47 | $-2.33 | ||
| Diluted EPS | -- | $-3.72 | $-4.48 | $-4.47 | $-2.33 | ||
| Diluted EPS (Continuing Operations) | -- | $-3.72 | $-4.48 | $-4.47 | $-2.33 | ||
| OTHER METRICS | |||||||
| Earnings from equity interest | -- | $-1.8M | $-16.3M | $-16.0M | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | $-1.8M | $-16.3M | $-16.0M | -- | ||
| Gain On Sale Of Business | -- | $51.6M | -- | -- | -- | ||
| Minority Interests | $707.0K | $7.4M | $307.0K | $114.0K | $28.0K | ||
| Other Gand A | $33.9M | $40.9M | $54.6M | $64.4M | $87.1M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | $5.0M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZNTL | $1.50 | +1.0% | 428.00K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Zentalis Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW